177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

Finn Edler Von Eyben, Aviral Singh, Jingjing Zhang, Karin Nipsch, Danielle Meyrick, Nat Lenzo, Kalevi Kairemo, Timo Joensuu, Irene Virgolini, Cigdem Soydal, Harshad R. Kulkarni, Richard Paul Baum

Research output: Contribution to journalArticle

Abstract

177 Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirtyfive patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 μg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected 177 Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92% (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or two bone metastases. Thirty-three docetaxel-naïve patients had a longer PSMA PET/CT progression-free survival than twelve patients who were resistant to docetaxel. Twenty-two patients who received LuPRLT with a cumulative injected 177 Lu activity ≥ 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177 Lu activity. Seventeen patients with relapse after LuPRLT who received rechallenge LuPRLT or ActPRLT had a better OS than five patients who received other forms for relapse treatment. LuPRLT gave mild and transitory adverse effects. The findings of the present study suggest that LuPRLT of patients with LNM may be effective and safe. The promising results motivate randomized phase II trials to further quantify the impact of LuPRLT as treatment of patients with LNM.

Original languageEnglish
Pages (from-to)2451-2461
Number of pages11
JournalOncotarget
Volume10
Issue number25
DOIs
Publication statusPublished - 29 Mar 2019

Fingerprint

Prostatic Neoplasms
Lymph Nodes
docetaxel
Therapeutics
Prostate-Specific Antigen
Disease-Free Survival
Neoplasm Metastasis
Bone and Bones
Recurrence
Survival
Castration

Cite this

Von Eyben, F. E., Singh, A., Zhang, J., Nipsch, K., Meyrick, D., Lenzo, N., ... Baum, R. P. (2019). 177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. Oncotarget, 10(25), 2451-2461. https://doi.org/10.18632/oncotarget.26789
Von Eyben, Finn Edler ; Singh, Aviral ; Zhang, Jingjing ; Nipsch, Karin ; Meyrick, Danielle ; Lenzo, Nat ; Kairemo, Kalevi ; Joensuu, Timo ; Virgolini, Irene ; Soydal, Cigdem ; Kulkarni, Harshad R. ; Baum, Richard Paul. / 177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. In: Oncotarget. 2019 ; Vol. 10, No. 25. pp. 2451-2461.
@article{a0946e89fdd94ca49681dfd1ab7f876d,
title = "177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer",
abstract = "177 Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirtyfive patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 μg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected 177 Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92{\%} (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or two bone metastases. Thirty-three docetaxel-na{\"i}ve patients had a longer PSMA PET/CT progression-free survival than twelve patients who were resistant to docetaxel. Twenty-two patients who received LuPRLT with a cumulative injected 177 Lu activity ≥ 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177 Lu activity. Seventeen patients with relapse after LuPRLT who received rechallenge LuPRLT or ActPRLT had a better OS than five patients who received other forms for relapse treatment. LuPRLT gave mild and transitory adverse effects. The findings of the present study suggest that LuPRLT of patients with LNM may be effective and safe. The promising results motivate randomized phase II trials to further quantify the impact of LuPRLT as treatment of patients with LNM.",
keywords = "Lutetium prostate specific membrane antigen radiolabeled radionuclide therapy, Metastatic prostate cancer, Overall survival, PSA response, Relapse treatment",
author = "{Von Eyben}, {Finn Edler} and Aviral Singh and Jingjing Zhang and Karin Nipsch and Danielle Meyrick and Nat Lenzo and Kalevi Kairemo and Timo Joensuu and Irene Virgolini and Cigdem Soydal and Kulkarni, {Harshad R.} and Baum, {Richard Paul}",
year = "2019",
month = "3",
day = "29",
doi = "10.18632/oncotarget.26789",
language = "English",
volume = "10",
pages = "2451--2461",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals, LLC",
number = "25",

}

Von Eyben, FE, Singh, A, Zhang, J, Nipsch, K, Meyrick, D, Lenzo, N, Kairemo, K, Joensuu, T, Virgolini, I, Soydal, C, Kulkarni, HR & Baum, RP 2019, '177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer' Oncotarget, vol. 10, no. 25, pp. 2451-2461. https://doi.org/10.18632/oncotarget.26789

177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. / Von Eyben, Finn Edler; Singh, Aviral; Zhang, Jingjing; Nipsch, Karin; Meyrick, Danielle; Lenzo, Nat; Kairemo, Kalevi; Joensuu, Timo; Virgolini, Irene; Soydal, Cigdem; Kulkarni, Harshad R.; Baum, Richard Paul.

In: Oncotarget, Vol. 10, No. 25, 29.03.2019, p. 2451-2461.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

AU - Von Eyben, Finn Edler

AU - Singh, Aviral

AU - Zhang, Jingjing

AU - Nipsch, Karin

AU - Meyrick, Danielle

AU - Lenzo, Nat

AU - Kairemo, Kalevi

AU - Joensuu, Timo

AU - Virgolini, Irene

AU - Soydal, Cigdem

AU - Kulkarni, Harshad R.

AU - Baum, Richard Paul

PY - 2019/3/29

Y1 - 2019/3/29

N2 - 177 Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirtyfive patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 μg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected 177 Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92% (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or two bone metastases. Thirty-three docetaxel-naïve patients had a longer PSMA PET/CT progression-free survival than twelve patients who were resistant to docetaxel. Twenty-two patients who received LuPRLT with a cumulative injected 177 Lu activity ≥ 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177 Lu activity. Seventeen patients with relapse after LuPRLT who received rechallenge LuPRLT or ActPRLT had a better OS than five patients who received other forms for relapse treatment. LuPRLT gave mild and transitory adverse effects. The findings of the present study suggest that LuPRLT of patients with LNM may be effective and safe. The promising results motivate randomized phase II trials to further quantify the impact of LuPRLT as treatment of patients with LNM.

AB - 177 Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirtyfive patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 μg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected 177 Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92% (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or two bone metastases. Thirty-three docetaxel-naïve patients had a longer PSMA PET/CT progression-free survival than twelve patients who were resistant to docetaxel. Twenty-two patients who received LuPRLT with a cumulative injected 177 Lu activity ≥ 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177 Lu activity. Seventeen patients with relapse after LuPRLT who received rechallenge LuPRLT or ActPRLT had a better OS than five patients who received other forms for relapse treatment. LuPRLT gave mild and transitory adverse effects. The findings of the present study suggest that LuPRLT of patients with LNM may be effective and safe. The promising results motivate randomized phase II trials to further quantify the impact of LuPRLT as treatment of patients with LNM.

KW - Lutetium prostate specific membrane antigen radiolabeled radionuclide therapy

KW - Metastatic prostate cancer

KW - Overall survival

KW - PSA response

KW - Relapse treatment

UR - http://www.scopus.com/inward/record.url?scp=85064868138&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26789

DO - 10.18632/oncotarget.26789

M3 - Article

VL - 10

SP - 2451

EP - 2461

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -